SWK Holdings Corp (SWKH)
SWK Holdings Corp (SWKH)
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 10,822 | NaN |
| Other revenue | 536 | NaN |
| Finance Receivables Segment-Operating Segments | -931 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 0 | NaN |
| Corporate Non Segment | 0 | NaN |
| Benefit (provision) for credit losses | -931 | NaN |
| Finance Receivables Segment-Operating Segments | 0 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 209 | NaN |
| Corporate Non Segment | 0 | NaN |
| Loss on impairment of intangibles assets | 209 | NaN |
| Interest expense | 3,464 | NaN |
| Finance Receivables Segment-Operating Segments | 0 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 147 | NaN |
| Corporate Non Segment | 0 | NaN |
| Pharmaceutical manufacturing, research and development expense | 1,550 | NaN |
| Finance Receivables Segment-Operating Segments | 0 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 314 | NaN |
| Corporate Non Segment | 0 | NaN |
| Loss on disposal of inventory | 314 | NaN |
| Finance Receivables Segment-Operating Segments | 0 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 0 | NaN |
| Corporate Non Segment | 2 | NaN |
| Depreciation and amortization expense | 2 | NaN |
| General and administrative expense | 9,406 | NaN |
| Other income (expense), net | 4,020 | NaN |
| Finance Receivables Segment-Operating Segments | 0 | NaN |
| Operating Segments-Pharmaceutical Development And Other Segment | 0 | NaN |
| Corporate Non Segment | 1,916 | NaN |
| Income tax expense | 4,220 | NaN |
| Net income | 8,780 | 8,075 |
| Provision (benefit) for credit losses | -931 | -704 |
| Loss on sale of assets | -82 | NaN |
| Loss on impairment of intangible assets | 209 | 0 |
| Right-of-use amortization and cease use costs | 31 | 112 |
| Amortization of debt issuance costs | 302 | 548 |
| Deferred income taxes, net | 1,890 | 2,266 |
| Unrealized net gain on warrants | -2,640 | 77 |
| Loss on disposal of inventory | 314 | NaN |
| Net gain from exercise and cancellation of warrants | 0 | 0 |
| Gain on sale of business | 1,476 | NaN |
| Change in fair value of acquisition-related contingent consideration | 0 | 0 |
| Loss from sale of assets | NaN | -82 |
| Loss (gain) on revaluation of finance receivables | 0 | -3,727 |
| Foreign currency transaction gains | 25 | 614 |
| Loss on marketable investments | -246 | -68 |
| Loan discount amortization and fee accretion | 3,005 | 2,956 |
| Debt issuance costs | NaN | 41 |
| Interest paid-in-kind | 756 | 826 |
| Stock-based compensation | 286 | 608 |
| Depreciation and amortization expense | 2 | 38 |
| Interest, accounts receivable and other receivables | -30 | -177 |
| Foreign currency forward contract | 0 | -915 |
| Collateral returned for foreign currency forward contract | 0 | -2,750 |
| Other assets | -424 | -850 |
| Accounts payable, accrued expenses, and other non-current liabilities | 484 | -871 |
| Deferred income | -3,300 | 1,800 |
| Net cash provided by operating activities | 906 | 16,081 |
| Proceeds from sale of property and equipment | 0 | 110 |
| Settlement of foreign currency forward contract | 0 | 1,560 |
| Proceeds from sale of assets and liabilities held for sale | 6,790 | NaN |
| Sale of marketable investments | 0 | 0 |
| Investment in finance receivables | 5,000 | 23,500 |
| Proceeds from sale of finance receivables | 0 | 31,678 |
| Repayment of finance receivables | 1,510 | 33,141 |
| Corporate debt securities principal payments | 8 | 15 |
| Purchases of property and equipment | 349 | 163 |
| Net cash provided by investing activities | 2,959 | 42,841 |
| Net settlement for employee taxes on stock options | 0 | -89 |
| Net payments on credit facility | -294 | -5,939 |
| Cash dividends | 0 | 49,078 |
| Payments of financing costs | 41 | NaN |
| Repurchases of common stock, including fees and expenses | 1,330 | 1,737 |
| Net cash used in financing activities | -1,665 | -56,843 |
| Net increase in cash and cash equivalents | 2,200 | 2,079 |
| Cash and cash equivalents at beginning of period | 5,927 | NaN |
| Cash and cash equivalents at end of period | 10,206 | NaN |